Maplight Therapeutics, Inc. (NASDAQ:MPLT) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Posted by George Bondi on Oct 18th, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) has earned an average rating of “Moderate Buy” from the eighteen ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $29.50.

Several research analysts have commented on MPLT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maplight Therapeutics in a research report on Friday, October 9th. Canaccord Genuity Group set a $21.00 price objective on Maplight Therapeutics in a research report on Friday, August 14th. Needham & Company LLC reduced their price objective on Maplight Therapeutics from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, August 31st. BMO Capital Markets began coverage on shares of Maplight Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $46.00 price objective on the stock. Finally, Wolfe Research reaffirmed an “outperform” rating and set a $30.00 target price on shares of Maplight Therapeutics in a research report on Monday, July 27th.

Check Out Our Latest Analysis on Maplight Therapeutics

Key Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

Positive Sentiment: MapLight Therapeutics is described as technically oversold after falling 29.2% over four weeks, potentially creating conditions for a rebound. Wall Street analysts have also been revising earnings estimates higher, providing a possible catalyst for a trend reversal. Down 29.2% in 4 Weeks, Here’s Why You Should You Buy the Dip in MapLight Therapeutics
Neutral Sentiment: CEO Christopher Kroeger sold 73,691 shares for approximately $595,423, while CFO Jonathan Gillis sold 10,167 shares for approximately $82,149. Both executives retained substantial holdings, and the filings said the sales covered tax obligations tied to equity vesting. CEO Form 4 Filing CFO Form 4 Filing
Negative Sentiment: Additional insiders Erin Pennock Foff, James Lillie and Anatol Kreitzer sold a combined 39,116 shares for roughly $313,118. Although these were also tax-withholding transactions, the cluster of insider selling can weigh on sentiment and add perceived supply pressure. Erin Pennock Foff Form 4 Filing James Lillie Form 4 Filing Anatol Kreitzer Form 4 Filing

Insider Activity

In related news, Director Troy Cox purchased 15,620 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were bought at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the transaction, the director directly owned 15,620 shares of the company’s stock, valued at approximately $148,702.40. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Christopher A. Kroeger sold 73,691 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $8.08, for a total transaction of $595,423.28. Following the transaction, the chief executive officer owned 1,195,909 shares in the company, valued at approximately $9,662,944.72. The trade was a 5.80% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 145,056 shares of company stock worth $1,267,599. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Maplight Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in Maplight Therapeutics during the second quarter worth about $37,000. Bank of New York Mellon Corp increased its stake in Maplight Therapeutics by 10.1% during the first quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock valued at $802,000 after acquiring an additional 3,608 shares during the period. Wellington Management Group LLP increased its stake in Maplight Therapeutics by 12.4% during the second quarter. Wellington Management Group LLP now owns 51,917 shares of the company’s stock valued at $1,861,000 after acquiring an additional 5,709 shares during the period. The Manufacturers Life Insurance Company acquired a new position in Maplight Therapeutics in the 2nd quarter valued at approximately $252,000. Finally, Deutsche Bank AG acquired a new position in Maplight Therapeutics in the 2nd quarter valued at approximately $370,000.

Maplight Therapeutics Stock Performance

NASDAQ MPLT opened at $7.70 on Tuesday. Maplight Therapeutics has a twelve month low of $7.46 and a twelve month high of $40.43. The stock has a market capitalization of $427.97 million and a PE ratio of -0.18. The stock has a 50-day simple moving average of $11.24 and a 200 day simple moving average of $22.37.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.40) by $0.08. As a group, equities research analysts forecast that Maplight Therapeutics will post -5.01 EPS for the current fiscal year.

About Maplight Therapeutics

(Get Free Report)

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric and neurological disorders. The company focuses on conditions for which existing treatments may provide limited benefits or cause significant side effects.

MapLight uses a neuroscience-focused drug discovery and development approach to identify therapies intended to address the underlying biology of central nervous system disorders. Its pipeline includes investigational small-molecule treatments being studied for conditions such as schizophrenia and other serious mental health disorders.

The company conducts research and clinical development in the United States.